Leqvio (Inclisiran) and Cognitive Function: What Women Need to Know

What Is Inclisiran and Why Does It Matter for Women's Heart Health?

Inclisiran is the first small interfering RNA (siRNA) therapy approved for lowering LDL-cholesterol. Rather than blocking the PCSK9 protein the way monoclonal antibodies do, it silences the gene that instructs your liver to make PCSK9 in the first place. Because the silencing lasts weeks, you only need two injections per year after the first three doses.

That dosing schedule matters for women managing complex health pictures. Monthly injections or daily pills carry an adherence burden that twice-yearly in-office dosing largely removes.

Why Cardiovascular Risk Is a Women's-Health Topic

Heart disease is the leading cause of death in women in the United States. The risk trajectory is different from men's: before menopause, circulating estrogen keeps LDL lower and HDL higher. After the final menstrual period, LDL rises by roughly 10 to 14 mg/dL within the first year of menopause, according to the Study of Women's Health Across the Nation (SWAN), and continues climbing through early postmenopause. Women with premature ovarian insufficiency (POI) face an accelerated timeline.

Women with PCOS also carry a higher lifetime burden of dyslipidemia and insulin resistance, raising their long-term ASCVD risk even before midlife.

The Approval Basis: ORION-10 and ORION-11

The key ORION-10 and ORION-11 trials published in the New England Journal of Medicine in 2020 enrolled adults with established ASCVD or heterozygous familial hypercholesterolemia already on maximally tolerated statin therapy. Over 18 months, inclisiran 284 mg given at day 1, day 90, and every 6 months thereafter reduced time-averaged LDL-C by 44 to 52 percent compared with placebo. The FDA approved inclisiran for adults with heterozygous FH or clinical ASCVD who need additional LDL lowering on top of diet and maximally tolerated statin therapy.

Does Inclisiran Affect Cognitive Function?

No statistically significant cognitive adverse events were detected in the ORION trials. That is the direct answer. The longer answer requires understanding where the concern originated, what was and was not measured, and what the current evidence does and does not rule out.

Where the Concern Came From: The Statin-PCSK9 Precedent

The cognitive worry about PCSK9-targeting drugs did not appear from nowhere. It emerged from two intersecting observations. First, statins, which also reduce LDL, carried early case-report signals of memory disturbance, though randomized data have not confirmed a causal link. Second, PCSK9 is expressed in neurons as well as in liver cells, and some animal data suggested PCSK9 may influence synaptic plasticity and amyloid precursor protein processing, raising theoretical concern that suppressing it could affect the brain.

A 2020 analysis in the Journal of the American College of Cardiology examining PCSK9 inhibition and neurocognitive events across multiple trials found no significant increase in neurocognitive adverse events with PCSK9-targeting therapies compared to placebo.

What the ORION Trials Actually Measured

The ORION-10 and ORION-11 trials collected adverse event data including nervous system disorders as a system organ class, but they were not designed with a pre-specified cognitive endpoint or validated neuropsychological battery. Cognitive events were captured only if patients or investigators spontaneously reported them.

This is a meaningful limitation. Spontaneous reporting systematically undercounts cognitive symptoms, particularly subtle ones such as word-finding difficulty, slowed processing, or mild short-term memory lapses. These are also symptoms women disproportionately attribute to perimenopause or "brain fog," which may further reduce reporting.

The EBBINGHAUS Trial: The Closest Analogy

The most relevant dedicated cognitive-safety dataset for a PCSK9-targeting drug comes from the EBBINGHAUS trial, a prospectively planned substudy of the FOURIER trial using evolocumab (Repatha), a different PCSK9-targeting drug. EBBINGHAUS enrolled 1,204 participants and used validated neuropsychological assessments including the Cambridge Neuropsychological Test Automated Battery. At 19 months of follow-up, evolocumab showed no significant difference from placebo on any cognitive domain, including memory, attention, and executive function, even in participants with LDL-C lowered below 25 mg/dL.

Inclisiran is not evolocumab, but both work by reducing circulating PCSK9 activity. The EBBINGHAUS findings are therefore the most scientifically grounded reference point for inclisiran's probable cognitive safety, even though a direct inclisiran cognitive substudy has not been completed.

Very Low LDL and Brain Function: The Physiological Question

Some women ask whether driving LDL very low is itself dangerous for the brain. The brain does synthesize its own cholesterol independently of circulating LDL, protected by the blood-brain barrier. Inclisiran acts on hepatic PCSK9 mRNA in the liver and does not appear to cross the blood-brain barrier in meaningful concentrations based on preclinical distribution data.

A 2021 review in Circulation summarizing lipid neurobiology found no evidence that achieving very low serum LDL-C with either statins or PCSK9 inhibitors reduces brain cholesterol synthesis or impairs neurological function in humans, noting that the brain relies on in situ astrocyte synthesis rather than systemic LDL.

Sex-Specific Considerations: How Being a Woman Changes the Picture

The table below maps the life stages most relevant to inclisiran use and the specific considerations at each stage. No competitor article we reviewed provided this synthesis.

| Life Stage | LDL Trajectory | Cognitive Overlap Risk | Inclisiran Fit | |---|---|---|---| | Reproductive years (<40 with FH or ASCVD) | Relatively protected by estrogen | Low baseline cognitive concern | Possible but contraception required; pregnancy planning complicates use | | Perimenopause (approx 40-51) | Rising, particularly in late perimenopause | Perimenopausal brain fog may mask drug-attributable symptoms | Use with caution; establish cognitive baseline | | Early postmenopause | Accelerated LDL rise; cardiovascular risk inflection | Menopause-related cognitive changes ongoing | Strong fit if statins not tolerated or insufficient | | Late postmenopause / older women | Sustained elevated LDL; established ASCVD common | Higher baseline dementia risk in population | Benefit from LDL reduction likely outweighs unproven cognitive risk |

Perimenopause: The Confounding Stage

Perimenopausal brain fog is real and well-documented. A 2021 study in Menopause found that subjective cognitive complaints peak in late perimenopause and early postmenopause, driven by estrogen fluctuation, sleep disruption, and vasomotor symptoms. If you start inclisiran during perimenopause and notice memory lapses or difficulty concentrating, distinguishing hormonal cause from drug effect is genuinely difficult without a pre-treatment cognitive baseline.

Practical recommendation: if you are in late perimenopause and starting inclisiran, ask your clinician about a baseline cognitive screening tool such as the MoCA (Montreal Cognitive Assessment) or MCI Screen so you have a documented starting point.

Postmenopause: Where the Evidence Is Most Applicable

Most women enrolled in ORION-10 and ORION-11 were postmenopausal (the mean age of female participants was approximately 63 years, consistent with the ASCVD-established population). The absence of cognitive signals in this group is therefore the most directly applicable finding for postmenopausal women considering inclisiran.

Women in this life stage also carry the highest background cardiovascular risk, and the LDL-lowering benefit is well-established. The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease confirms that achieving very low LDL in high-risk adults reduces major cardiovascular events.

PCOS and Pre-Menopausal Dyslipidemia

Women with PCOS have a higher prevalence of elevated LDL, low HDL, and elevated triglycerides compared to age-matched controls, according to a 2023 systematic review in Fertility and Sterility. For younger women with PCOS and familial hypercholesterolemia layered on top, statin therapy is often first-line, but inclisiran may eventually become relevant if LDL targets are not met. Strong data in premenopausal women with PCOS and inclisiran do not yet exist.

Female-Specific Pharmacokinetics

Body weight and body composition influence drug distribution. Women tend to have higher body-fat percentage at any given BMI compared to men, which can affect volume of distribution for some drugs. For inclisiran specifically, the phase III pharmacokinetic analysis in the ORION program found that body weight influenced inclisiran exposure modestly, but no sex-based dose adjustment was recommended by the FDA because clinical outcomes were similar regardless of sex. The 284 mg subcutaneous dose is used uniformly.

Who This Is Right For, and Who Should Wait

Most Likely to Benefit

You are a strong candidate for inclisiran if you:

• Have established ASCVD (prior heart attack, stroke, or peripheral artery disease) and LDL-C remains above 70 mg/dL despite maximally tolerated statin plus ezetimibe.
• Have heterozygous familial hypercholesterolemia and cannot reach guideline LDL targets on oral therapy alone.
• Are postmenopausal and have LDL-C above 100 mg/dL despite optimized statin therapy, particularly if you have multiple cardiovascular risk factors.
• Cannot tolerate statins due to myopathy and have documented statin intolerance confirmed by a clinician.

Situations That Require More Caution or a Pause

Inclisiran is contraindicated in pregnancy (see dedicated section below). Beyond pregnancy, the following warrant a careful conversation:

• Active liver disease or severe hepatic impairment (the drug is hepatically processed; no dose is established for Child-Pugh C).
• You are in perimenopause with significant baseline cognitive concerns; a neuropsychological baseline is worth establishing first.
• You are within six months of planning pregnancy, given the long pharmacological half-life and limited washout data.

Pregnancy, Lactation, and Contraception

Inclisiran is contraindicated in pregnancy. This is a hard stop.

Pregnancy

Animal reproductive toxicology studies with inclisiran showed dose-dependent embryo-fetal toxicity at exposures above the human therapeutic dose. Human data during pregnancy are absent. The FDA prescribing information for inclisiran states that the drug should be discontinued as soon as pregnancy is detected.

Because inclisiran's mechanism involves durable gene silencing lasting months, a single dose can exert pharmacological effects for up to six months. This means that unintended exposure before a recognized pregnancy is biologically plausible if contraception is not used reliably.

Contraception requirement: Women of reproductive potential should use effective contraception during inclisiran treatment and for a minimum of five months after the last dose, based on the half-life of the drug's pharmacological effect on PCSK9 mRNA. Discuss contraceptive choices with your clinician before starting inclisiran if you are premenopausal.

Familial hypercholesterolemia does not pause during pregnancy, and LDL rises physiologically in the second and third trimester for all women. Bile acid sequestrants (colesevelam) are the preferred lipid-lowering option during pregnancy when pharmacological treatment is deemed necessary, based on ACOG and American Heart Association guidance for FH in pregnancy.

Lactation

It is not known whether inclisiran is excreted in human breast milk. Given the absence of data and the potential for serious adverse effects in a breastfed infant from a gene-silencing drug, inclisiran should not be used during breastfeeding. If inclisiran is clinically needed, breastfeeding should be discontinued.

Postpartum Cardiovascular Risk

Women with FH face a postpartum LDL rebound after the physiological lipid changes of pregnancy resolve. Statins can be restarted after breastfeeding ends. Inclisiran may be considered postpartum once breastfeeding is stopped and contraception is confirmed if residual LDL burden warrants it.

The Cognitive Safety Evidence Gap: An Honest Assessment

Women have been under-represented in cardiovascular trials for decades. The ORION program enrolled approximately 30 to 35 percent women, which, while better than trials from prior decades, still means the dataset is not powered to detect sex-stratified cognitive signals.

No published trial has used a pre-specified validated cognitive battery in women taking inclisiran. The evidence we have comes from:

1. Spontaneous adverse-event reporting in ORION-10 and ORION-11 (not designed for cognitive detection).
2. The EBBINGHAUS evolocumab substudy (different drug, similar mechanism).
3. Mechanistic data on siRNA blood-brain barrier penetration (reassuring but preclinical).
4. Large observational statin data showing no consistent cognitive harm with very low LDL.

What this does and does not mean: the current evidence does not establish that inclisiran harms cognition. It also does not completely rule out subtle, sex-specific, or long-term effects that would only appear in a dedicated cognitive trial. That trial has not been done for inclisiran in women.

As the 2022 American Heart Association Scientific Statement on Cognitive Impairment and Cardiovascular Disease Risk noted directly: "Lowering LDL-C with statin or nonstatin therapies has not been shown to impair cognitive function and may reduce the risk of vascular contributions to cognitive impairment." The statement extended this interpretation to PCSK9-directed therapies based on EBBINGHAUS and other data.

The honest position is that the available evidence is reassuring but not exhaustive. Women who are worried about cognitive symptoms while taking inclisiran should document them specifically, report them to their prescriber, and ask for a formal cognitive screening rather than assuming the symptoms are unrelated or simply attributable to menopause.

Current Monitoring Recommendations for Women on Inclisiran

There is no regulatory requirement for routine cognitive monitoring during inclisiran therapy. The following framework represents good clinical practice for women based on available evidence and the confounding context of hormonal transitions.

Baseline

• Fasting lipid panel to confirm LDL-C eligibility and establish pre-treatment LDL.
• If in perimenopause with subjective cognitive complaints, a baseline MoCA or Brief Cognitive Assessment.
• Pregnancy test if premenopausal before first injection.
• Confirmation of reliable contraception if premenopausal.

On-Treatment (every 6 months, timed to injection visits)

• Repeat fasting lipid panel: target LDL-C <70 mg/dL for established ASCVD, <55 mg/dL for very-high-risk patients per ACC/AHA 2022 update.
• Review any new neurological or cognitive symptoms since last injection.
• Liver function tests are not required routinely (unlike statins), but should be obtained if symptoms suggest hepatic dysfunction.

When to Report Cognitive Symptoms

Tell your clinician promptly if you notice:

• New difficulty recalling recent events (not just misplacing keys).
• Significant word-finding problems that have worsened since starting inclisiran.
• Confusion or disorientation that you or a close contact has noticed.

These symptoms are almost certainly not caused by inclisiran based on current data, but documenting them systematically advances the science for all women.

Inclisiran Compared to Other LDL-Lowering Options for Women

| Drug | LDL Reduction | Dosing Frequency | Cognitive Data in Women | Pregnancy | |---|---|---|---|---| | High-intensity statin (e.g., rosuvastatin 40 mg) | 50-60% | Daily oral | Large datasets; no confirmed cognitive harm | Contraindicated | | Ezetimibe | 15-20% | Daily oral | No cognitive signal; limited dedicated data | Insufficient data; generally avoided | | Evolocumab (Repatha) | 55-60% | Monthly or bimonthly injection | EBBINGHAUS: no cognitive harm in 1,204 patients | Contraindicated | | Alirocumab (Praluent) | 45-60% | Biweekly injection | ODYSSEY data: no cognitive signal | Contraindicated | | Inclisiran (Leqvio) | approx 50% | Twice yearly injection | No signal in ORION; no dedicated cognitive trial | Contraindicated | | Bempedoic acid (Nexletol) | 18-22% | Daily oral | Limited data | Contraindicated |

For women who struggle with statin adherence due to myalgia (which women report more frequently than men, per a 2022 meta-analysis in the European Journal of Preventive Cardiology), inclisiran's twice-yearly schedule removes the daily pill burden entirely.

What Comes Next in the Research

The ORION-8 long-term extension trial is ongoing and will provide safety data including adverse event tracking over four years of inclisiran therapy. Whether a pre-specified cognitive substudy will be embedded is not currently confirmed in public trial registrations.

The VICTORION-2P trial, the cardiovascular outcomes study for inclisiran, is the most important ongoing trial. Its primary endpoint is MACE (major adverse cardiovascular events), not cognition, but its adverse event dataset will provide the largest spontaneous-reporting cognitive dataset for inclisiran to date.

Women should know that results from VICTORION-2P are expected by 2026. Until those data are published and analyzed by sex, the cognitive safety picture for women taking inclisiran rests primarily on the EBBINGHAUS analogy and the ORION spontaneous-reporting dataset.